EU expands approval of ALK’s house dust mite pill
European regulators have expanded the scope of ALK-Abello’s Acarizax to include the treatment of adolescent patients with house dust mite-induced allergic rhinitis.
Read More
Tag: house dust mite
Circassia abandons allergy programme after trial failure
British biotech Circassia has announced the death of its allergy programme following a second key trial failure, choosing to focus all of its efforts on its respiratory business instead.
Read More
US approval for ALK’s house dust mite pill
US regulators have approved Odactra, the first allergen extract to be administered under the tongue to treat house dust mite (HDM)-induced nasal inflammation (allergic rhinitis) in people 18 through 65 years of age.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
